Form 8-K - Current report:
SEC Accession No. 0000950170-25-073950
Filing Date
2025-05-19
Accepted
2025-05-19 07:15:09
Documents
12
Period of Report
2025-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K itrm-20250513.htm   iXBRL 8-K 53827
2 EX-99.1 itrm-ex99_1.htm EX-99.1 22557
3 GRAPHIC img185001215_0.jpg GRAPHIC 26891
  Complete submission text file 0000950170-25-073950.txt   229223

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itrm-20250513.xsd EX-101.SCH 25787
14 EXTRACTED XBRL INSTANCE DOCUMENT itrm-20250513_htm.xml XML 4709
Mailing Address 3 DUBLIN LANDINGS NORTH WALL QUAY DUBLIN 1 L2 D01 H104
Business Address 3 DUBLIN LANDINGS NORTH WALL QUAY DUBLIN 1 L2 D01 H104 (872) 225-6077
Iterum Therapeutics plc (Filer) CIK: 0001659323 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38503 | Film No.: 25961487
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)